paroxetine has been researched along with reserpine in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaatz, GW; Kerns, RJ; Wei, P | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Brincat, JP; Carosati, E; Cruciani, G; Fravolini, A; Kaatz, GW; Manfroni, G; Patel, D; Raygada, JL; Sabatini, S | 1 |
| Cecchetti, V; Gosetto, F; Kaatz, GW; Manfroni, G; Patel, D; Sabatini, S; Tabarrini, O | 1 |
| Brincat, JP; Carosati, E; Cecchetti, V; Gosetto, F; Iraci, N; Kaatz, GW; Manfroni, G; Sabatini, S; Serritella, S; Tabarrini, O; Villarini, M | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Barreca, ML; Cecchetti, V; Dimovska, M; Gosetto, F; Iraci, N; Kaatz, GW; Manfroni, G; Massari, S; Sabatini, S; Sancineto, L; Tabarrini, O | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hekmatpanah, CR; McKenna, DJ; Peroutka, SJ | 1 |
| Fuller, RW | 1 |
| Gobbi, M; Mennini, T; Palacios, JM; Pompeiano, M; Regondi, MC | 1 |
| Costentin, J; Leroux-Nicollet, I; Naudon, L; Raisman-Vozari, R; Vilpoux, C | 1 |
| Kadioglu, M; Kalyoncu, NI; Kesim, M; Ozyavuz, R; Ulku, C; Yaris, E | 1 |
| Hasegawa, R; Ikeda, K; Karasawa, J; Tamura, K; Yamamoto, H; Yamamoto, T; Yasumoto, S | 1 |
| Bhatt, S; Devadoss, T; Jindal, A; Kumar, B; Mahesh, R; Pandey, DK | 1 |
| Bagmetova, VV; Chernysheva, YV; Ozerov, AA; Tyurenkov, IN | 1 |
2 review(s) available for paroxetine and reserpine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Biochemical pharmacology of the serotonin system.
Topics: Alanine; Brain; Citalopram; Clomipramine; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; Monoamine Oxidase Inhibitors; Neurons; Oximes; p-Chloroamphetamine; Paroxetine; Piperidines; Propylamines; Receptors, Serotonin; Reserpine; Serotonin; Serotonin Antagonists; Synapses; Tetrabenazine; Zimeldine | 1986 |
16 other study(ies) available for paroxetine and reserpine
| Article | Year |
|---|---|
Structural differences between paroxetine and femoxetine responsible for differential inhibition of Staphylococcus aureus efflux pumps.
Topics: Bacterial Proteins; Biological Transport, Active; Drug Resistance, Multiple, Bacterial; Paroxetine; Piperidines; Staphylococcus aureus; Structure-Activity Relationship | 2004 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Discovery of novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Benzimidazoles; Ciprofloxacin; Databases, Factual; Drug Resistance, Bacterial; Drug Synergism; Ethidium; Microbial Sensitivity Tests; Models, Molecular; Multidrug Resistance-Associated Proteins; Phenyl Ethers; Propanolamines; Quantitative Structure-Activity Relationship; Staphylococcus aureus; Structure-Activity Relationship; Sulfonamides | 2011 |
Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Drug Synergism; Flavones; Hydroxyquinolines; Microbial Sensitivity Tests; Models, Chemical; Molecular Structure; Multidrug Resistance-Associated Proteins; Mutation; Species Specificity; Staphylococcus aureus; Structure-Activity Relationship | 2011 |
Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Resistance, Multiple, Bacterial; Drug Synergism; Microbial Sensitivity Tests; Models, Molecular; Multidrug Resistance-Associated Proteins; Pyrazoles; Small Molecule Libraries; Staphylococcus aureus; Structure-Activity Relationship; Sulfonamides; Thiazines | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Chemistry Techniques, Synthetic; Computer-Aided Design; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Inhibitory Concentration 50; Ligands; Microbial Sensitivity Tests; Models, Molecular; Molecular Conformation; Multidrug Resistance-Associated Proteins; Quinolines; Staphylococcus aureus; Structure-Activity Relationship | 2013 |
Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Cerebral Cortex; Corpus Striatum; Designer Drugs; Dopamine; Male; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Endings; Nervous System Diseases; Paroxetine; Piperidines; Rats; Rats, Inbred Strains; Reserpine; Serotonin | 1989 |
Differential effects of 5,7-dihydroxytryptamine-induced serotoninergic degeneration of 5-HT1A receptors and 5-HT uptake sites in the rat brain.
Topics: 5,7-Dihydroxytryptamine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Autoradiography; Brain; Citalopram; Male; Nerve Degeneration; Paroxetine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Reserpine; Serotonin | 1994 |
Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain.
Topics: Animals; Autoradiography; Binding Sites; Biological Transport; Brain; Citalopram; Dopamine; Immunohistochemistry; In Situ Hybridization; In Vitro Techniques; Ligands; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neuropeptides; Norepinephrine; Paroxetine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Reserpine; Selective Serotonin Reuptake Inhibitors; Serotonin; Tetrabenazine; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2000 |
The effects of paroxetine on rat isolated vas deferens.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Adenosine Triphosphate; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Electric Stimulation; Epididymis; Male; Muscle Contraction; Muscle, Smooth; Norepinephrine; Paroxetine; Potassium Chloride; Rats; Rats, Sprague-Dawley; Reserpine; Vas Deferens | 2003 |
Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2.
Topics: Animals; Dopamine; Fluoxetine; Fluvoxamine; Haloperidol; Male; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Rats; Rats, Wistar; Reserpine; Selective Serotonin Reuptake Inhibitors; Synaptic Vesicles; Vesicular Monoamine Transport Proteins | 2009 |
Antidepressant and anxiolytic-like effects of 4n, a novel 5-HT3 receptor antagonist using behaviour based rodent models.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Emotions; Mice; Olfactory Bulb; Ondansetron; Paroxetine; Photoperiod; Quinoxalines; Rats; Rats, Wistar; Reserpine; Serotonin 5-HT3 Receptor Antagonists; Swimming | 2012 |
Comparison of the Efficiency of Adeprophen and Antidepressants of Various Groups on the Model of Reserpine-Induced Depression in Rats.
Topics: Adenine; Amitriptyline; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Fluoxetine; Food Preferences; Imipramine; Male; Motor Activity; Paroxetine; Rats; Reserpine; Sertraline; Venlafaxine Hydrochloride | 2016 |